A phase III single-arm study of a new 13.5 mg levonorgestrel intrauterine contraceptive system in postmenarcheal adolescents: an evaluation of efficacy, bleeding, user satisfaction, and placement

Abstract

To evaluate the efficacy, bleeding profile and user satisfaction associated with the 13.5 mg total content levonorgestrel intrauterine contraceptive system (LNG-IUS13.5mg; Skyla in the US, Jaydess elsewhere) in postmenarcheal adolescents, and to evaluate the placement of LNG-IUS13.5mg in this group. Safety (primary outcome) data are presented in another abstract.